From: Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma
EGFR | Age-ranges (years) | Pathologic subtype | TNM stage | Smoking |
---|---|---|---|---|
L858R mutation | 50–60 | adenocarcinoma | IV | 0 |
L858R mutation | 50–60 | adenocarcinoma | IV | 300, 30 |
L858R mutation | 70–80 | adenocarcinoma | IB | 0 |
L858R mutation | 70–80 | adenocarcinoma | IV | 0 |
L858R mutation | 70–80 | adenocarcinoma | IV | 1600, 10 |
L858R mutation | 70–80 | adenocarcinoma | IB | 0 |
L858R mutation | 70–80 | adenocarcinoma | IV | 450 |
L858R mutation | 60–70 | adenocarcinoma | IV | 200 |
L858R mutation | 60–70 | adenocarcinoma | IV | 0 |
L858R mutation | 60–70 | adenocarcinoma | IV | 0 |
L858R mutation | 50–60 | adenocarcinoma | IV | 0 |
L858R mutation | 60–70 | adenocarcinoma | IV | 0 |
L858R mutation | 50–60 | adenocarcinoma | IV | 0 |
L858R mutation | 80–90 | adenocarcinoma | IV | 0 |
L858R mutation | 60–70 | adenocarcinoma | IV | 0 |
L858R mutation | 70–80 | adenocarcinoma | IV | 0 |
L858R mutation | 40–50 | adenocarcinoma | IIA | 0 |
L858R mutation | 50–60 | adenocarcinoma | IV | 0 |
L858R mutation | 60–70 | adenocarcinoma | IV | 0 |
L858R mutation | 60–70 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 30–50 | adenocarcinoma | IIIB | 100 |
Exon 19 deletion | 50–60 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 60–70 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 40–50 | adenocarcinoma | p-IIIB | 0 |
Exon 19 deletion | 50–60 | adenocarcinoma | IV | 450, 10 |
Exon 19 deletion | 50–60 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 60–70 | adenocarcinoma | IV | 300 |
Exon 19 deletion | 60–70 | non-small cell lung cancer | IV | 140 |
Exon 19 deletion | 60–70 | adenocarcinoma | IV | 800 |
Exon 19 deletion | 70–80 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 80–90 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 60–70 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 60–70 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 50–60 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 70–80 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 60–70 | adenocarcinoma | IV | 800, 1 |
Exon 19 deletion | 70–80 | adenocarcinoma | IV | 1800 |
Exon 19 deletion | 60–70 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 60–70 | adenocarcinoma | cT4N3Mx | 0 |
Exon 19 deletion | 40–50 | adenocarcinoma | IV | 0 |
Exon 19 deletion | 40–50 | adenocarcinoma | IV | 200 |
Wild type | 60–70 | adenocarcinoma | IV | 600 |
Wild type | 60–70 | adenocarcinoma | IV | 2400 |
Wild type | 50–60 | mediastinal malignant tumor | ? | 600 |
Wild type | 60–70 | non-small cell lung cancer | IIIB | 0 |
Wild type | 50–60 | adenocarcinoma | IV | 600 |
Wild type | 60–70 | small cell lung cancer | IIIB | 1000 |
Wild type | 50–60 | non-small cell lung cancer | IIIA | 0 |
Wild type | 60–70 | adenocarcinoma | IV | 800 |
Wild type | 60–70 | adenocarcinoma | p-IIA | 800, 7 |
Wild type | 60–70 | small cell lung cancer | IV | 800 |
Wild type | 60–70 | squamous cell carcinoma | cT4N2Mx | 0 |
Wild type | 60–70 | small cell lung cancer | IV | 0 |
Wild type | 70–80 | adenocarcinoma | IIIB | 0 |
Wild type | 60–70 | non-small cell lung cancer | IIIB | 1600 |
Wild type | 60–70 | non-small cell lung cancer | cT3N3Mx | 1200 |
Wild type | 60–70 | adenocarcinoma | IIB | 1600, 2 |
Wild type | 60–70 | neuroendocrine carcinoma | IV | 800 |
Wild type | 70–80 | squamous cell carcinoma | IIIA | 1200 |
Wild type | 60–70 | adenocarcinoma | IV | 1200 |
Wild type | 50–60 | non-small cell lung cancer | IV | 0 |